

HUMAN ANTIBODIES & HYBRIDOMAS

22-24 October 2018, Pullman Riga Old Town Hotel, Riga, Latvia

FIRST CIRCULAR AND CALL FOR PARTICIPATION FOR HAH 2018

Sponsored by the International Journal Human Antibodies - In association with the Integrative Medical Sciences Association

The 23rd HUMAN ANTIBODIES & HYBRIDOMAS conference will be held at the Pullman Riga Old Town Hotel in Riga, the capital city of Latvia.

The HAH 2018 scientific programme will have a broadened scope from previous events with the addition of some new topics, areas outlined in the scope section below. As usual the scientific programme will include keynote lectures, contributed oral papers and poster presentations encompassing all key aspects of human antibody technology, applications and engineering.

SCIENTIFIC ADVISORY PANEL

Programme Chairman: Professor Mark Gately JACOB Marmar Cancer Center, San Diego, California, USA

Mark Gately (New York University School of Medicine, New York, USA)

Henry Lowman (Genentech Inc., South San Francisco, California, USA)

Chris Scott (The Clayton Foundation, Belmont, Northern Ireland, UK)

Robert Stuber (University of California, San Diego, La Jolla, CA, USA)

Jon Latham (Pfizer Research, New York, USA)

Joel Long (Johnson & Johnson, Germany)

David P. Henschen (JCB, Bielefeld, UK)

Markus Gressinger (Abnova AG, Switzerland, Germany)

Enrico Nigg (Novartis GmbH, Vienna, Austria)

Sachdev Indu (University of Toronto, Canada)

Scott Wells (J&J, Cambridge, UK)

Pam New (Pfizer Antibodies, Northern Ireland, UK)

Rob W. Johnson (Pharmaceuticals LLC, New York, USA)

Rob W. Johnson (Pharmaceuticals LLC, New York, USA)

David Rhee (City of Science University, Amsterdam, Holland)

David Rhee (City of Science University, Amsterdam, Holland)

Andy Berry (Genentech, San Francisco, California, USA)

Mary Gwynne (Medimmune, Cambridge, UK)

Dale Lukens (Amgen Inc., San Jose, USA)

Herman Kottgen and Oritsa Kottgen

Pharmaceuticals (University of Göttingen, Göttingen, Germany)

Andrew Searles (Alphatec Therapeutics, Seattle, Washington, USA)

CONFERENCE SCOPE

The scope of the HAH 2018 conference falls broadly into the following main session categories:

Infectious Diseases - Autoimmunity - Molecular Biology - Emerging Technologies/Clinical Applications
Therapeutic Antibodies - Cancer - Anti-Infective Antibodies - Intellectual Property & Legal Issues

For the 2018 and future meetings the scope is being expanded to include sessions on:

Formulation - Oral Delivery - Combination Therapy - Validity of Animal Models
Peptide Drugs - Immunobiology of Cancer & Autoimmunity

